Cargando…

Alternative starting regimen with aripiprazole long-acting treatments, a case report

INTRODUCTION: Aripiprazole long-acting treatments can significantly control symptom, improve adherence and reduce the risk of relapse compared to oral drugs. An alternative start-up guideline has recently been approved in several countries that simplifies its administration. OBJECTIVES: To present a...

Descripción completa

Detalles Bibliográficos
Autores principales: Huete Naval, M., Serván, B., Expósito Durán, M.E., Albarracin, P., Herrero Pellón, E., Galerón, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568249/
http://dx.doi.org/10.1192/j.eurpsy.2022.1866
_version_ 1784809601268449280
author Huete Naval, M.
Serván, B.
Expósito Durán, M.E.
Albarracin, P.
Herrero Pellón, E.
Galerón, R.
author_facet Huete Naval, M.
Serván, B.
Expósito Durán, M.E.
Albarracin, P.
Herrero Pellón, E.
Galerón, R.
author_sort Huete Naval, M.
collection PubMed
description INTRODUCTION: Aripiprazole long-acting treatments can significantly control symptom, improve adherence and reduce the risk of relapse compared to oral drugs. An alternative start-up guideline has recently been approved in several countries that simplifies its administration. OBJECTIVES: To present a case report of a patient with schizophrenia treated with alternative starting regimen of aripiprazole long-acting treatment. METHODS: Presentation of a clinical case supported by a non-systematic review of literature. RESULTS: We present the case of a 22-year-old patient diagnosed with schizophrenia, whose symptoms started after the birth of her son, 2 years ago. She has presented a poor clinical evolution, requiring several admissions to our inpatient service after discontinuation of her medication. The patient has taken different antipsychotics, including olanzapine and paliperidone long-acting treatment, which were suspended due to side effects (weight gain and increased prolactin levels). A switch to oral aripiprazole 20mg was made, which showed good response and tolerance. Given the persistence of irregular intake, it was decided to switch to aripiprazole long-acting treatment, applying an alternative initial regime consisting of two doses of aripiprazole long-acting treatments 400mg and one oral aripiprazole 20mg. The patient has since had no delusions or hallucinations and is living independently at home. CONCLUSIONS: The administration of a simplified initial regime with aripiprazole long-acting treatments could improve therapeutic adherence while maintaining the same effectiveness and similar side effects. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9568249
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95682492022-10-17 Alternative starting regimen with aripiprazole long-acting treatments, a case report Huete Naval, M. Serván, B. Expósito Durán, M.E. Albarracin, P. Herrero Pellón, E. Galerón, R. Eur Psychiatry Abstract INTRODUCTION: Aripiprazole long-acting treatments can significantly control symptom, improve adherence and reduce the risk of relapse compared to oral drugs. An alternative start-up guideline has recently been approved in several countries that simplifies its administration. OBJECTIVES: To present a case report of a patient with schizophrenia treated with alternative starting regimen of aripiprazole long-acting treatment. METHODS: Presentation of a clinical case supported by a non-systematic review of literature. RESULTS: We present the case of a 22-year-old patient diagnosed with schizophrenia, whose symptoms started after the birth of her son, 2 years ago. She has presented a poor clinical evolution, requiring several admissions to our inpatient service after discontinuation of her medication. The patient has taken different antipsychotics, including olanzapine and paliperidone long-acting treatment, which were suspended due to side effects (weight gain and increased prolactin levels). A switch to oral aripiprazole 20mg was made, which showed good response and tolerance. Given the persistence of irregular intake, it was decided to switch to aripiprazole long-acting treatment, applying an alternative initial regime consisting of two doses of aripiprazole long-acting treatments 400mg and one oral aripiprazole 20mg. The patient has since had no delusions or hallucinations and is living independently at home. CONCLUSIONS: The administration of a simplified initial regime with aripiprazole long-acting treatments could improve therapeutic adherence while maintaining the same effectiveness and similar side effects. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9568249/ http://dx.doi.org/10.1192/j.eurpsy.2022.1866 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Huete Naval, M.
Serván, B.
Expósito Durán, M.E.
Albarracin, P.
Herrero Pellón, E.
Galerón, R.
Alternative starting regimen with aripiprazole long-acting treatments, a case report
title Alternative starting regimen with aripiprazole long-acting treatments, a case report
title_full Alternative starting regimen with aripiprazole long-acting treatments, a case report
title_fullStr Alternative starting regimen with aripiprazole long-acting treatments, a case report
title_full_unstemmed Alternative starting regimen with aripiprazole long-acting treatments, a case report
title_short Alternative starting regimen with aripiprazole long-acting treatments, a case report
title_sort alternative starting regimen with aripiprazole long-acting treatments, a case report
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568249/
http://dx.doi.org/10.1192/j.eurpsy.2022.1866
work_keys_str_mv AT huetenavalm alternativestartingregimenwitharipiprazolelongactingtreatmentsacasereport
AT servanb alternativestartingregimenwitharipiprazolelongactingtreatmentsacasereport
AT expositoduranme alternativestartingregimenwitharipiprazolelongactingtreatmentsacasereport
AT albarracinp alternativestartingregimenwitharipiprazolelongactingtreatmentsacasereport
AT herreropellone alternativestartingregimenwitharipiprazolelongactingtreatmentsacasereport
AT galeronr alternativestartingregimenwitharipiprazolelongactingtreatmentsacasereport